In a setback for tech giant Apple, the U.S. International Trade Commission (ITC) has denied the company’s plea to postpone the ban on Apple Watch Series 9 and Apple Watch Ultra 2 sales amid an ongoing patent dispute with medical device maker Masimo. The ban, effective since December 26, stems from the ITC’s October ruling that the watches’ SpO2 sensors infringe on Masimo’s patents.
Apple initially responded by removing the affected models from its website and retail locations on December 21 and 24, respectively. The ban not only halts sales but also restricts out-of-warranty repairs for certain Apple Watch models, impacting users of Series 6 and later devices (excluding SE).
Despite Apple’s “strong disagreement” with the ITC’s decision, the U.S. Trade Representative, Catherine Tye, declined to overturn the ban, making the tribunal’s ruling final. Apple has swiftly appealed to the U.S. Court of Appeals for the Federal Circuit in Washington, DC, signaling its determination to resume sales.
In a bid to address the patent infringement, Apple is developing a software update, though Masimo contends that hardware modifications are necessary. The ITC’s ban has prompted speculation that Apple’s appeal could prolong the case for approximately another year, causing uncertainty for Apple Watch enthusiasts and impacting the company’s financial outlook.
The dispute underscores broader concerns surrounding intellectual property rights and the delicate balance between technological innovation and legal obligations. Apple’s proactive approach to resolving the matter demonstrates the significance of maintaining a harmonious relationship between tech companies and other industries impacted by their advancements.